Breaking News Instant updates and real-time market news.

AKCA

Akcea Therapeutics

$24.91

-1.19 (-4.56%)

, IONS

Ionis Pharmaceuticals

$67.61

-4.03 (-5.63%)

16:24
05/07/19
05/07
16:24
05/07/19
16:24

Akcea Therapeutics, Ionis Pharmaceuticals announce new Tegsedi data at AAN

Akcea Therapeutics (AKCA) and Ionis Pharmaceuticals (IONS) announced new long-term, open-label extension, or OLE, data from the NEURO-TTR study of Tegsedi in patients with hereditary ATTR amyloidosis, or hATTR, with polyneuropathy. The data was highlighted as an oral presentation at the American Academy of Neurology, or AAN. Hereditary ATTR amyloidosis is a disease that is caused by the buildup of TTR proteins that misfold due to inherited mutations. hATTR is characterized by the deposition of amyloid fibrils throughout the body, including the nerves and can have a devastating impact on the patients' quality of life, or QoL. Tegsedi is a once-weekly at-home subcutaneous injection that targets hATTR amyloidosis with polyneuropathy at its source by reducing the production of TTR protein. Of the 139 patients who completed the NEURO-TTR phase 3 study, 97% of patients elected to continue in the OLE study. Initiation of TEGSEDI, substantially reduced TTR protein levels 75%-79% below baseline and sustained reductions throughout treatment. Patients who received Tegsedi through the NEURO-TTR and OLE studies continued to show benefit throughout, and patients who switched from placebo to Tegsedi demonstrated an improvement in measures of neuropathy progression and QoL compared with a continued predicted worsening with placebo. Additionally, patients who initiated Tegsedi as part of the OLE demonstrated a stabilization of neurologic disease progression by mNIS+7 and Norfolk QoL-DN within six months, while greater benefit in mNIS+7 and Norfolk QoL-DN was observed in patients treated earlier with Tegsedi. No new safety signals were identified in the open-label extension study.

AKCA

Akcea Therapeutics

$24.91

-1.19 (-4.56%)

IONS

Ionis Pharmaceuticals

$67.61

-4.03 (-5.63%)

  • 08

    May

  • 09

    May

  • 14

    May

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

AKCA Akcea Therapeutics
$24.91

-1.19 (-4.56%)

09/18/18
NEED
09/18/18
INITIATION
Target $45
NEED
Buy
Akcea Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Akcea Therapeutics (AKCA) with a Buy rating and a price target of $45, saying it is an "attractive" way for investors to leverage "decades of innovation" by the parent Ionis Pharma (IONS) through ownership of its most advanced-stage programs. The analyst cites the unfolding "breakthrough" in the approval of a new class of antisense drugs which "directly block protein synthesis in cells by binding to RNA". Messer adds that Akcea is positioned for near-term commercial opportunity for its Tegsedi and Waylivra programs.
10/07/18
PIPR
10/07/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam's Onpattro highly efficacious, safer than competitor, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Ionis Pharmaceuticals (IONS) announced FDA approval of TEGSEDI for treatment of hATTR polyneuropathy. The analyst also points out that the label includes a Black Box warning for thrombocytopenia and glomerulonephritis requiring every 2-week monitoring, and will be marketed by Ionis subsidiary Akcea (AKCA) with a Risk Evaluation and Mitigation Strategy. TEGSEDI is administered subcutaneously every week versus Alnylam's (ANLY) ONPATTRO intravenously every 3 weeks with steroids, he adds. Tenthoff believes that ONPATTRO appears safer and highly efficacious, and should win out. The analyst reiterates an Overweight rating and $160 price target on Alnylam shares.
10/08/18
CANT
10/08/18
INITIATION
Target $135
CANT
Overweight
Cantor reiterates Overweight on Alnylam after Akcea, Ionis win approval
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $135 price target after the FDA approved Tegsedi, to be marketed by Akcea Therapeutics (AKCA). The analyst says that while the approval introduces another competitor to the market, she still expects Alnylam's Onpattroto be able to take significant share in the polyneuropathy hATTR market. Young thinks the Tegsedi label is more onerous and currently models a 60% peak share to Alnylam, a 25% share to Tegsedi and 15% to future competition.
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
IONS Ionis Pharmaceuticals
$67.61

-4.03 (-5.63%)

04/17/19
WELS
04/17/19
NO CHANGE
WELS
Outperform
Ionis pullback on Roche update a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators.
04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".
05/07/19
PIPR
05/07/19
NO CHANGE
Target $142
PIPR
Overweight
Piper more confident in estimates for Alnylam's Onpattro after doctor survey
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $142 price target after surveying 16 physicians treating 490 hereditary transthyretin amyloidosis patients with polyneuropathy. Doctors have a "clear preference" for Alnylam's Onpattro over Onpattro and Ionis Pharmaceuticals' (IONS) Tegsedi, with efficacy, safety, and experience being cited, Tenthoff tells investors in a research note. Roughly two-thirds of existing and new gene silencer patients are prescribed Onpattro, says the analyst. Based on the survey results, the analyst is increasingly confident in his 2019 Onpattro sales estimates of $127M.
05/07/19
MSCO
05/07/19
NO CHANGE
MSCO
Biogen could rise, or fall, 5% based on Zolgensma label, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Novartis' (NVS) gene therapy for the rare disease spinal muscular atrophy, Zolgensma, is expected to be approved by the FDA this month. He also noted that Biogen's (BIIB) Spinraza is currently the only approved drug for SMA and represents 17% of Biogen's estimated 2019 sales. The public data for Novartis' Zolgensma are only in type 1 patients, or infants, said Harrison, who sees three potential scenarios for the drug's label. In the first, which would involve broad approval across the three patient classes of infants, children and adults, Harrison thinks Novartis shares could be up 1-2%, Biogen could fall about 5%, Ionis (IONS), which receives royalties from Biogen, could be down about 10%, and Regenxbio (RGNX), which will receive royalties from Novartis, could be up 10-15% or more. In the second case, where Zolgensma is granted a Type 1 approval with no restriction, Harrison sees Novartis unchanged, Biogen down 1-3%, Ionis falling 3-5% and Regenxbio rising 5%. In the third scenario, where Zolgensma gets a Type 1 approval but with a weight/age restriction, the analyst thinks Novartis would be down 1-2%, Biogen would be up 2-3%, Ionis could rise 5% and Regenxbio could fall 5-10%. Harrison's base case assumption is that Zolgensma will ultimately capture the majority market share in type 1 patients and a "significant portion" of type 2, or pediatric, patients.

TODAY'S FREE FLY STORIES

NVS

Novartis

$87.04

2.58 (3.05%)

12:47
05/24/19
05/24
12:47
05/24/19
12:47
Hot Stocks
Novartis says wholesale acquisition cost of Zolgensma $2.125M »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TIVO

TiVo

$6.87

0.04 (0.59%)

12:45
05/24/19
05/24
12:45
05/24/19
12:45
Options
TiVo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

12:45
05/24/19
05/24
12:45
05/24/19
12:45
General news
Breaking General news story  »

Week of 5/24 Baker-Hughes…

VWAGY

Volkswagen

$0.00

(0.00%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Appeals court rules in favor of Volkswagen diesel car owners, Reuters reports »

A German appeals court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$56.30

0.85 (1.53%)

, WCG

WellCare

$267.57

-6.89 (-2.51%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Third Point confirms Centene stake to CNBC, says WellCare deal in best interest »

CNBC tweeted: "Third…

CNC

Centene

$56.30

0.85 (1.53%)

WCG

WellCare

$267.57

-6.89 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

, IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

12:40
05/24/19
05/24
12:40
05/24/19
12:40
Technical Analysis
On The Fly: ETF fund flow highlights »

Flows for the past week…

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

XLK

Technology Select Sector SPDR

$73.62

0.33 (0.45%)

SMH

Market Vectors Semiconductor

$100.37

0.23 (0.23%)

SOXX

iShares PHLX Semiconductor ETF

$180.13

0.06 (0.03%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$119.60

0.14 (0.12%)

EEM

iShares MSCI Emerging Markets ETF

$40.00

0.08 (0.20%)

XLU

Utilities SPDR

$59.99

0.07 (0.12%)

XLV

Health Care Select Sector SPDR

$89.56

0.17 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$126.65

0.46 (0.36%)

, CCOEY

Capcom

$0.00

(0.00%)

12:37
05/24/19
05/24
12:37
05/24/19
12:37
Hot Stocks
Microsoft says Project xCloud can stream more than 3,500 games »

Kareem Choudhry,…

MSFT

Microsoft

$126.65

0.46 (0.36%)

CCOEY

Capcom

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

NVS

Novartis

$86.93

2.47 (2.92%)

12:33
05/24/19
05/24
12:33
05/24/19
12:33
Hot Stocks
Novartis announces FDA approval for Zolgensma »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

CNC

Centene

$55.37

-0.08 (-0.14%)

, WCG

WellCare

$273.18

-1.28 (-0.47%)

12:33
05/24/19
05/24
12:33
05/24/19
12:33
Periodicals
Third Point thinks Centene should consider sale before buying WellCare, WSJ says »

Daniel Loeb's Third…

CNC

Centene

$55.37

-0.08 (-0.14%)

WCG

WellCare

$273.18

-1.28 (-0.47%)

HUM

Humana

$262.97

3.1 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 05

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

  • 13

    Nov

NVS

Novartis

$86.95

2.49 (2.95%)

12:31
05/24/19
05/24
12:31
05/24/19
12:31
Hot Stocks
Breaking Hot Stocks news story on Novartis »

Novartis announces FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

KNX

Knight-Swift

$29.75

-0.65 (-2.14%)

12:30
05/24/19
05/24
12:30
05/24/19
12:30
Options
Volatility play opened in Knight Transportation »

Volatility play opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 13

    Nov

WCG

WellCare

$273.55

-0.91 (-0.33%)

, CNC

Centene

$55.41

-0.04 (-0.07%)

12:27
05/24/19
05/24
12:27
05/24/19
12:27
Periodicals
Breaking Periodicals news story on WellCare, Centene »

Activist Third Point has…

WCG

WellCare

$273.55

-0.91 (-0.33%)

CNC

Centene

$55.41

-0.04 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

WCG

WellCare

$273.55

-0.91 (-0.33%)

, CNC

Centene

$55.41

-0.04 (-0.07%)

12:26
05/24/19
05/24
12:26
05/24/19
12:26
Periodicals
Breaking Periodicals news story on WellCare, Centene »

Third Point thinks…

WCG

WellCare

$273.55

-0.91 (-0.33%)

CNC

Centene

$55.41

-0.04 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

FLEX

Flex

$9.39

-0.08 (-0.84%)

12:25
05/24/19
05/24
12:25
05/24/19
12:25
Periodicals
Huawei phone assembler Flex stops production at China factory, NAR says »

Flex, Huawei's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$357.37

6.8 (1.94%)

12:23
05/24/19
05/24
12:23
05/24/19
12:23
Periodicals
SEC probing Boeing disclosures on grounded 737 Max, Bloomberg reports »

The SEC is investigating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SNA

Snap-On

$157.57

0.25 (0.16%)

12:20
05/24/19
05/24
12:20
05/24/19
12:20
Options
Bullish call spread in Snap On will create its biggest open interest »

Bullish call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
05/24/19
05/24
12:17
05/24/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
05/24/19
05/24
12:16
05/24/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$358.20

7.63 (2.18%)

, SMI

SMIC

$5.18

-0.315 (-5.74%)

12:13
05/24/19
05/24
12:13
05/24/19
12:13
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are finishing out…

BA

Boeing

$358.20

7.63 (2.18%)

SMI

SMIC

$5.18

-0.315 (-5.74%)

FL

Foot Locker

$44.14

-8.705 (-16.47%)

HPQ

HP Inc.

$20.06

0.865 (4.51%)

HPE

HP Enterprise

$14.64

0.31 (2.16%)

TSS

TSYS

$110.03

10.42 (10.46%)

GPN

Global Payments

$152.60

4.63 (3.13%)

HIBB

Hibbett Sports

$24.25

4.405 (22.20%)

DVAX

Dynavax

$5.33

-1.03 (-16.20%)

SPLK

Splunk

$117.39

-11.29 (-8.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 09

    Jul

  • 09

    Jul

  • 13

    Nov

ACHC

Acadia

$32.58

0.35 (1.09%)

12:13
05/24/19
05/24
12:13
05/24/19
12:13
Conference/Events
Acadia to hold a strategic update conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

BA

Boeing

$357.94

7.365 (2.10%)

12:12
05/24/19
05/24
12:12
05/24/19
12:12
Hot Stocks
Breaking Hot Stocks news story on Boeing »

Boeing off highs, still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

BA

Boeing

$357.77

7.2 (2.05%)

12:12
05/24/19
05/24
12:12
05/24/19
12:12
Periodicals
Breaking Periodicals news story on Boeing »

SEC probing Boeing over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SWKS

Skyworks

$69.32

0.77 (1.12%)

12:10
05/24/19
05/24
12:10
05/24/19
12:10
Options
Call buyer loading up on Skyworks July 70s »

Call buyer loading up on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

TSS

TSYS

$109.69

10.08 (10.12%)

, GPN

Global Payments

$152.48

4.51 (3.05%)

12:09
05/24/19
05/24
12:09
05/24/19
12:09
Periodicals
Global Payments near deal to acquire TSYS for $20B in stock, CNBC reports »

Global Payments (GPN) is…

TSS

TSYS

$109.69

10.08 (10.12%)

GPN

Global Payments

$152.48

4.51 (3.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 05

    Jun

  • 13

    Nov

ESV

Ensco Rowan

$8.56

-0.285 (-3.22%)

12:05
05/24/19
05/24
12:05
05/24/19
12:05
Options
Ensco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.